Weekly Respiratory Research Analysis
This week’s respiratory literature highlights translational host‑directed therapeutics, mechanistic niche signalling in pulmonary immunity, and population-level prevention evidence. A Nature Communications preclinical paper presents HA‑coated siRNA nanoparticles targeting TDRD9 to promote neutrophil cuproptosis and reduce Pseudomonas lung injury. A Journal of Experimental Medicine study defines oxysterol–GPR183 signalling as an instructive niche cue for monocyte‑to‑macrophage differentiation in
Summary
This week’s respiratory literature highlights translational host‑directed therapeutics, mechanistic niche signalling in pulmonary immunity, and population-level prevention evidence. A Nature Communications preclinical paper presents HA‑coated siRNA nanoparticles targeting TDRD9 to promote neutrophil cuproptosis and reduce Pseudomonas lung injury. A Journal of Experimental Medicine study defines oxysterol–GPR183 signalling as an instructive niche cue for monocyte‑to‑macrophage differentiation in the lung. A population-based Eurosurveillance analysis using target‑trial emulation shows single‑dose nirsevimab substantially lowered infant RSV hospitalisations across two seasons.
Selected Articles
1. Tudor domain-containing protein 9-targeting siRNA nanoparticles alleviate Pseudomonas aeruginosa lung injury in preclinical models by promoting neutrophil cuproptosis.
HA‑coated peptide nanoparticles delivering siRNA against TDRD9 targeted neutrophils, enhanced neutrophil cuproptosis, reduced neutrophil accumulation, and ameliorated lung inflammation and edema in Pseudomonas aeruginosa models and human lung organoids. Mechanistic work implicates PD‑L1/CD80–p38 MAPK signalling in TDRD9‑mediated suppression of cuproptosis; silencing TDRD9 reversed this and reduced bacterial burden.
Impact: Demonstrates a translational, host‑directed nanoparticle strategy that leverages immune cell death pathways (cuproptosis) to treat bacterial pneumonia, integrating human omics, mechanistic biology, and organoid/murine models.
Clinical Implications: If safety and dosing translate to humans, this host‑directed approach could complement antibiotics for MDR Pseudomonas pneumonia by reducing injurious neutrophil accumulation; requires GLP toxicology and early‑phase clinical trials.
Key Findings
- HA‑si‑TDRD9 nanoparticles targeted neutrophils and reduced lung inflammation and edema in mouse P. aeruginosa pneumonia models.
- TDRD9 suppresses neutrophil cuproptosis via PD‑L1/CD80-mediated activation of p38 MAPK; silencing TDRD9 enhances cuproptosis and reduces bacterial growth in human lung organoids.
2. Sensing of metabolic signals via GPR183 promotes occupation of lung macrophage niches by monocytes.
Using conditional macrophage depletion and longitudinal single‑cell RNA sequencing, the study shows fibroblast‑derived 7α,25‑diOH‑cholesterol engages GPR183 on recruited monocytes, positioning them to occupy vacated lung macrophage niches and differentiate into interstitial macrophages. GPR183 deficiency impairs niche occupation, identifying an instructive oxysterol‑GPR183 axis for tissue macrophage development.
Impact: Defines a previously unrecognized ligand–receptor niche axis (oxysterol–GPR183) that instructs monocyte‑to‑macrophage differentiation in lung tissue, revealing a tractable pathway to modulate macrophage repopulation in injury, infection, or fibrosis.
Clinical Implications: Pharmacologic modulation of GPR183 or its ligand gradients could be developed to enhance beneficial macrophage repopulation after lung injury or to limit maladaptive macrophage programs in chronic lung disease; translational studies are needed.
Key Findings
- Interstitial macrophages express GPR183 and newcomer monocyte‑derived macrophages upregulate GPR183 during differentiation after niche depletion.
- Fibroblasts supply 7α,25‑diOH‑cholesterol in empty niches to engage GPR183 and instruct monocyte‑to‑macrophage differentiation; GPR183 loss impairs this process.
3. Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.
A population‑based case‑control study employing target‑trial emulation (cloning, censoring, IPW) estimated that a single nirsevimab dose reduced RSV hospitalisations by ~64–67% across two infant seasons, with very high first‑season effectiveness (78–84%) and attenuated second‑season estimates possibly biased by survivor effects. No rebound in hospitalisations among immunised children was observed.
Impact: Provides timely, policy‑relevant, population‑scale causal estimates that single‑dose nirsevimab markedly reduces infant RSV hospitalisations, informing immunisation strategies and resource planning.
Clinical Implications: Supports broad first‑season prophylaxis with nirsevimab to reduce RSV hospital burden, while highlighting the need to monitor second‑season durability, equity of access, and targeted strategies for high‑risk groups.
Key Findings
- Two‑season effectiveness (catch‑up and at‑birth) was 64% and 67%, respectively, with first‑season effectiveness 78–84% and attenuated second‑season estimates.
- Target‑trial emulation methods (cloning/censoring/IPW) were used to estimate causal per‑protocol effects from observational data; no second‑season rebound in hospitalisations among immunised children was detected.